Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial Second Candidate from Company’s P2X3 Development Pipeline to Enter the Clinic San Mateo, CA – December 8, 2015 – Afferent Pharmaceuticals, a leader in the development of small molecule...
QPID Health to Showcase New Approach to Quality Reporting at the IHI Forum on Quality Improvement in Healthcare Company to demonstrate software that streamlines reporting processes and finds more patient data to improve performance Boston – December 1, 2015 – QPID...
iRhythm Technologies Launches New iOS App Enabling Patients to Report Irregular Heartbeat Symptoms for Physician Diagnosis iRhythm myZIO™ smartphone app and website to increase patient engagement with company’s leading arrhythmia detection service SAN FRANCISCO,...
True North Therapeutics Announces $40 Million Series C Financing Company to Advance Clinical Program for Lead Complement Inhibitor, TNT009, in Cold Agglutinin Disease and Other Rare Diseases South San Francisco, CA, December 3, 2015— True North Therapeutics, a...
Recent Comments